Clinical trial
Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or…
NCT00457574 · Gemin X, Industry · Withdrawn
Key facts
| NCT number | NCT00457574 |
|---|---|
| Title | Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas |
| Official title | A Single-Center, Open-Label, Phase I Study of Single-Agent GMX1777 Administered as a 24-Hour Infusion Every 3 Weeks to Patients With Refractory Solid Tumors or Lymphomas |
| Lead sponsor | Gemin X, Industry |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors and Lymphomas |
| Intervention type | Drug |
| Interventions | GMX1777 |
| Enrollment | 0 |
| Start date | Mar 1, 2007 |
| Primary completion | Jul 1, 2009 |
| Completion | Aug 1, 2010 |
| First posted | Apr 6, 2007 |
| Last update posted | Aug 28, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: